Jan 04, 2023 8:05am EST Ensysce Biosciences Announces Successful Completion of Clinical Portion of Oral Human Abuse Potential Trial
Dec 19, 2022 8:05am EST Ensysce Biosciences Announces Data from PF614-MPAR-101-Part A Successfully Demonstrating Opioid Overdose Protection
Dec 05, 2022 8:05am EST Ensysce Biosciences Announces Completion of Clinical Portion of Overdose Protection Trial PF614-MPAR-101-Part A
Nov 14, 2022 8:05am EST Ensysce Biosciences Announces FDA Guidance on the Clinical Development Pathway for PF614
Oct 31, 2022 8:05am EDT Ensysce Biosciences Announces Positive Topline Results of Clinical Study Evaluating Human Abuse Potential of Intranasal Administration of PF614, a TAAP Abuse-Deterrent Oxycodone Extended-Release Product
Oct 28, 2022 9:40am EDT Ensysce Biosciences Announces First Subjects Dosed in Second Human Abuse Potential Study
Oct 12, 2022 8:05am EDT Ensysce Biosciences, Inc. Announces Participation in LD Micro Main Event XV Conference